A series of furoxan derivatives were studied for their ability to interact with P-gp and MRP1 transporters in MDCK cells overexpressing these proteins. 3-Phenylsulfonyl substituted furoxans emerged as the most interesting compounds. All of them were capable of inhibiting P-gp, and a few also MRP1. Substituents at the 4-position of 3-phenylsulfonylfuroxan scaffold were able to modulate the selectivity and the intensity of inhibition. In some cases, they reverted MRP1 inhibitor activity, namely they were capable of potentiating MRP1 dependent efflux. When two of the tested compounds (16 and 17) were co-administered with doxorubicin they restored a high degree of the activity of the antibiotic. Preliminary immunoblotting studies carried out on these two compounds indicate that they are capable of nitrating P-gp, which in this form is likely unable to efflux the antibiotic.
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein
FRUTTERO, Roberta;CROSETTI, MARCO;CHEGAEV, Konstantin;GUGLIELMO, Stefano;GASCO, Alberto;
2010-01-01
Abstract
A series of furoxan derivatives were studied for their ability to interact with P-gp and MRP1 transporters in MDCK cells overexpressing these proteins. 3-Phenylsulfonyl substituted furoxans emerged as the most interesting compounds. All of them were capable of inhibiting P-gp, and a few also MRP1. Substituents at the 4-position of 3-phenylsulfonylfuroxan scaffold were able to modulate the selectivity and the intensity of inhibition. In some cases, they reverted MRP1 inhibitor activity, namely they were capable of potentiating MRP1 dependent efflux. When two of the tested compounds (16 and 17) were co-administered with doxorubicin they restored a high degree of the activity of the antibiotic. Preliminary immunoblotting studies carried out on these two compounds indicate that they are capable of nitrating P-gp, which in this form is likely unable to efflux the antibiotic.File | Dimensione | Formato | |
---|---|---|---|
JMC_2010_MDR.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.14 MB
Formato
Adobe PDF
|
1.14 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Supporting_Information.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
196.62 kB
Formato
Adobe PDF
|
196.62 kB | Adobe PDF | Visualizza/Apri |
Manuscript.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
679.55 kB
Formato
Adobe PDF
|
679.55 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.